Teva in $7.4 billion Barr buy

Share this article:
Teva is buying Montvale, NJ-based Barr Pharmaceuticals for $7.4 billion and will take on debt of $1.5 billion.

The move gives the Jerusalem-based generics giant a host of generic drugs, branded contraceptives, including Seasonique and Plan B, and access to Eastern European markets. It comes at a time when generics' share of the US market is surging. With the acquisition, Teva will have a quarter of the US market, said president and CEO Shlomo Yanai in an interview with Bloomberg.
 
Together, the companies employ around 37,000 in 60 countries and had nearly $12 billion in revenues in 2007.
 
Last year, generics accounted for 67% of total US dispensed prescriptions according to IMS Health.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions